Atreca Inc logo

BCEL - Atreca Inc Share Price

$10.41 -0.4  -3.6%

Last Trade - 05/05/21

Small Cap
Market Cap £286.9m
Enterprise Value £114.1m
Revenue £n/a
Position in Universe 3813th / 6846
Unlock BCEL Revenue
Relative Strength (%)
1m -23.3%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -56.9%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, AtrecaInc revenues was not reported. Net loss increased 28% to$86.3M. Higher net loss reflects General and administrativeincrease of 37% to $20.2M (expense), Research anddevelopment - Balancing increase of 9% to $56.2M (expense),Stock-based Compensation in SGA increase from $3.1M to$6.6M (expense). Basic Earnings per Share excludingExtraordinary Items decreased from -$2.41 to -$2.70.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


BCEL Revenue Unlock BCEL Revenue

Net Income

BCEL Net Income Unlock BCEL Revenue

Normalised EPS

BCEL Normalised EPS Unlock BCEL Revenue

PE Ratio Range

BCEL PE Ratio Range Unlock BCEL Revenue

Dividend Yield Range

BCEL Dividend Yield Range Unlock BCEL Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
BCEL EPS Forecasts Unlock BCEL Revenue
Profile Summary

Atreca, Inc. is a biotechnology company. The Company is engaged in developing therapeutics drawn from human immune responses, including anti-cancer immune responses. Its portfolio programs are focused on applications in cancer treatment. The Company’s lead product candidate, ATRC-101, is a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using our discovery platform. The Company's Immune Repertoire Capture (IRC) technology, which enables us to accurately reconstruct the original antibody sequences from a single B cell in parallel with other B cells in the sample. Its IRC tracks the co-expression of genes from the same single cell and TCRs are recovered. IRC generates sequence information from the beginning of signal sequences through constant regions of immunoglobulins, delivering variable domains and isotype information.

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated June 11, 2010
Public Since June 20, 2019
No. of Shareholders: 66
No. of Employees: 130
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 36,890,970
Free Float (0.0%)
Eligible for
BCEL Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for BCEL
Upcoming Events for BCEL
Frequently Asked Questions for Atreca Inc
What is the Atreca Inc share price?

As of 05/05/21, shares in Atreca Inc are trading at $10.41, giving the company a market capitalisation of £286.9m. This share price information is delayed by 15 minutes.

How has the Atreca Inc share price performed this year?

Shares in Atreca Inc are currently trading at $10.41 and the price has moved by -37.68% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Atreca Inc price has moved by -57.36% over the past year.

What are the analyst and broker recommendations for Atreca Inc?

There are no analysts currently covering Atreca Inc.

When will Atreca Inc next release its financial results?

Atreca Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Atreca Inc dividend yield?

Atreca Inc does not currently pay a dividend.

Does Atreca Inc pay a dividend?

Atreca Inc does not currently pay a dividend.

When does Atreca Inc next pay dividends?

Atreca Inc does not currently pay a dividend.

How do I buy Atreca Inc shares?

To buy shares in Atreca Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Atreca Inc?

Shares in Atreca Inc are currently trading at $10.41, giving the company a market capitalisation of £286.9m.

Where are Atreca Inc shares listed? Where are Atreca Inc shares listed?

Here are the trading details for Atreca Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: BCEL
What kind of share is Atreca Inc?

Based on an overall assessment of its quality, value and momentum, Atreca Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Atreca Inc share price forecast 2021?

Shares in Atreca Inc are currently priced at $10.41. At that level they are trading at 0.18% discount to the analyst consensus target price of 0.00.

Analysts covering Atreca Inc currently have a consensus Earnings Per Share (EPS) forecast of -2.715 for the next financial year.

How can I tell whether the Atreca Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Atreca Inc. Over the past six months, the relative strength of its shares against the market has been -32.99%. At the current price of $10.41, shares in Atreca Inc are trading at -26.76% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Atreca Inc PE Ratio?

We were not able to find PE ratio data for Atreca Inc.

Who are the key directors of Atreca Inc?

Atreca Inc's management team is headed by:

Tito Serafini - OTH
David Lacey - IND
Lisa Decker - OTH
Courtney Phillips - GCN
John Orwin - PRE
Herbert Cross - CFO
Brian Atwood - NEC
Franklin Berger - IND
William Robinson - DRC
Kristine Ball - DRC
Who are the major shareholders of Atreca Inc?

Here are the top five shareholders of Atreca Inc based on the size of their shareholding:

Baker Bros. Advisors LP Hedge Fund
Percentage owned: 11.71% (3.53m shares)
Wellington Management Company, LLP Investment Advisor/Hedge Fund
Percentage owned: 11.13% (3.36m shares)
Redmile Group, LLC Investment Advisor/Hedge Fund
Percentage owned: 8.21% (2.48m shares)
EcoR1 Capital, LLC Hedge Fund
Percentage owned: 8.04% (2.43m shares)
Boxer Capital, L.L.C. Hedge Fund
Percentage owned: 7.3% (2.20m shares)
Similar to BCEL
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.